Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.86 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.86 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.60 |
| ▸ | WDR5 | P61964 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882270 | 0.93 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2WDR5 | |
| SCHEMBL4882946 | 0.93 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2WDR5 | |
| SCHEMBL10733982 | 0.88 | PTGDR2 (0.68) | PTGDR2PTGDRPTGER2WDR5POLB | |
| SCHEMBL17113009 | 0.78 | PTGDR2 (0.88) | PTGDR2PTGDRPTGER2 | |
| SCHEMBL1615073 | 0.77 | PKM (0.70) | PTGDR2PTGDRPOLBTSHRCTDSP1 | |
| SCHEMBL4879219 | 0.77 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2TDP1 | |
| SCHEMBL21095340 | 0.77 | PTGDR2 (0.92) | PTGDR2PTGDRPTGER2 | |
| SCHEMBL23599384 | 0.76 | SLC6A4 (0.56) | PTGDR2PTGDR | |
| SCHEMBL3044855 | 0.76 | PTGDR2 (0.79) | PTGDR2PTGDRPOLBTSHRCTDSP1 | |
| SCHEMBL4886140 | 0.75 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | claimed |
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | disclosed |
| CN-111491628-B | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3723746-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| EP-3723746-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111491628-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2019115780-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PTGDR2 2581/4885PTGDR 2725/4885PTGER2 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.